The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
Conditions: Immune Thrombocytopenia; Blood Platelet Disorder; Hematologic Diseases; Purpura, Thrombocytopenic; Purpura; Blood Coagulation Disorder; Thrombotic Microangiopathies; Hemorrhagic Disorders; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Pathologic Processes; Skin Manifestations; Thrombocytopenia; Purpura, Thrombocytopenic, Idiopathic; Primary Immune Thrombocytopenia; ITP - Immune Thrombocytopenia Interventions: Drug: HMPL-523 Sponsors: Hutchmed Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Conditions: Behcet ' s Disease; Idiopathic Inflammatory Myopathies; IgG4-related Disease Interventions: Drug: Filgotinib Sponsors: UMC Utrecht; Alfasigma S.p.A.; ReumaNederland; Autoimmune Research and Collaboration Hub Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
FKC288 in Participants With Autoimmune Kidney Diseases
Conditions: Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy, IgG4-related Diseases Interventions: Drug: FKC288 Sponsors: Nanjing University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
Conditions: Autoimmune Diseases Interventions: Biological: CD19-BAFF Targeted CAR T-cells Sponsors: Zhejiang University; Shanghai YaKe Biotechnology Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Systemic Treatments for Alopecia Areata Registry
Conditions: Alopecia Areata; Alopecia Totalis; Alopecia Universalis; Hair Loss; Hair Diseases; Alopecia; Alopecia Drugs; Autoimmune Diseases Sponsors: Erasmus Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
X-linked Moesin Associated Immunodeficiency
Conditions: Immune Deficiency; Autoimmune Diseases; Infections; Diagnosis Interventions: Genetic: genetic restrospective study Sponsors: Institut National de la Sant é Et de la Recherche Médicale, France Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Analysis of TPE Treatments With multiFiltratePRO
Conditions: Autoimmune Diseases Interventions: Device: Therapeutic Plasma Exchange (TPE) option of multiFiltratePRO Sponsors: Fresenius Medical Care Deutschland GmbH; X-act Cologne Clinical Research GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Systems-level analyses of immune dysregulation
Conditions: Immunodeficiency; Autoimmune Diseases; Autoinflammatory Syndrome; Allergy; Dysregulated Host Response Interventions: Combination Product: Immunomodulation Sponsors: Karolinska Institutet; Karolinska University Hospital; Skane University Hospital; Sahlgrenska University Hospital, Sweden; Uppsala University Hospital; Region Halland; Region J önköping County Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Conditions: Systemic Lupus Erythematosus (SLE); Immune-Mediated Necrotizing Myopathy; Neuromyelitis Optica Spectrum Disorders; Multiple Sclerosis-Relapsing-Remitting Interventions: Biological: CD20/BCMA-directed CAR-T cells Sponsors: RenJi Hospital; AbelZeta Pharma Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases
Conditions: Autoimmune Diseases Interventions: Genetic: JY231 Sponsors: Shanxi Bethune Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 6, 2024 Category: Research Source Type: clinical trials
Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions
Conditions: Genetic Diseases; Immune Dysfunction; Neurological Disease; Autoimmune Diseases Interventions: Other: Biological Samples Sponsors: Imagine Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Conditions: Autoimmune Hemolytic Anemia; Autologous CD19 CAR-T; Failure of Three or More Lines of Therapy Interventions: Biological: CNCT19 CAR-T cell therapy Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Juventas Cell Therapy Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
EMERYVILLE, Calif., Jan. 19, 2024. Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it received... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy
Conditions: Autoimmune Hemolytic Anemia; CD19 CAR-T Cell Infusion Interventions: Biological: ThisCART19A Sponsors: Institute of Hematology& Blood Diseases Hospital, China; Suzhou Fundamenta Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials
F01 in the Treatment of Autoimmune Diseases
Conditions: Autoimmune Diseases Interventions: Drug: After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated. Sponsors: RenJi Hospital; Shanghai Simnova Biotechnology Co.,Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
